Today’s AI Top Pick: KVYO

8/25/2026 · Swing Setup + Squeeze screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live KVYO price forecast →

Today's pick · Swing Setup + SqueezeKVYOBUY NOW8.5 / 108/25/2026

Klaviyo is the cleanest setup in the pool right now: it is the only name with confirmed near-term bullish signal (near_term_bullish=1, bullish_prob=1.0) AND the strongest fundamentals block in the group (fundamental_score 7.25 vs. next best 5.5). The screen thesis is validated hard here — recom 1.26, targetUpsidePct 46.4%, epsNextY +28.28%, salesYoY +28.89%, fwdPe 17.21 with a peg of 0.67, and a short float of 16.22% that can fuel the squeeze mechanic the lens is designed to capture. Multi-timeframe forecasts agree in the direction that matters for a swing: 4h fc_short +18.97%, fc_mid +39.43%, fc_long +32.81%; 1d fc_short +2.04%, fc_mid +12.73%, fc_long +27.81%. The daily tape isn't stretched (pos_in_21bar_range 56%, dd -6.25%) and the weekly is still mid-range (54.86%, dd -18.2% from the 21-bar high) — so we get a runner-up drawdown to buy without chasing. The 4h is elevated (92% of range) but that's what you'd expect from a name that just turned; the daily/weekly give room. The weekly fc_long of -1.75% is the one blemish, worth calling out, but the daily long forecast of +27.81% carries more weight for a 2–6 week swing. The news slate is a green light: Aug 20 SeekingAlpha "Tremendous New Product Momentum" and Aug 12 earnings with "Solid Top-Line Performance" — the gross-margin caveat is real but not thesis-breaking. No litigation, no dilution, no short-seller piece. Compare to KRMN whose 4h fc_mid of +58.91% looks like an outlier reading (single-bar chase risk, no 1wk data, bullish_prob null, fwdPe 54.74), or DAVE/GRND/DLO whose forecast tapes are decisively DOWN across every horizon despite good fundamental_scores — the screen catches these but the tape says they're rolling over. Why TODAY: KVYO just came out of Q2 with a positive analyst take, sits ~6% off the daily 21-bar high with RSI 52.6 (room to run before overbought), forward P/E under 18 on 28% top-line growth is rare, and both near-term probability and forecast magnitudes align. Waiting risks missing the squeeze impulse; the size of the mid/long 4h and 1d forecasts (+39% / +27%) is where the asymmetric payoff lives.

KVYO forecast chart
Entry zone
$17.90–$18.30 (scale in around current $18.16; add on a pullback into $17.60 gap-fill if offered)
Stop loss
$16.80 close (below the 1d 21-bar dd zone, ~-7.5%; hard stop $16.40)
First target
$20.50–$21.00 (roughly aligns with 4h fc_short +18.97% and 1d fc_mid +12.73%)
Longer target
$23.00–$25.00 (aligns with 4h fc_mid/long +32–39% and 1d fc_long +27.81%)
Risks
  • Gross margin guidance was trimmed at Q2 (Aug 12 SeekingAlpha) — if Q3 margin compression accelerates, the fwdPe 17.21 story cracks fast.
  • Weekly fc_long is -1.75% and weekly fc_short is -7.36%, so the higher-timeframe tape is not fully confirming the daily/4h thrust.
  • PE of 858 and operMargin of -1.86% mean this is still a growth-narrative name — a 3–5% market drawdown could pressure -15% here given 44% YTD underperformance.
  • Short float 16.22% cuts both ways — great if it squeezes, brutal if the tape breaks $17 support.
  • 4h pos_in_21bar_range at 92% means you're buying into a short-term extended reading; a same-day fade is possible before the trend resumes.
Honorable mentions
KRMNMassive forecast magnitudes (4h fc_mid +58.91%, 1d fc_mid +38.89%) with mid-range positioning (49.65%/36.93%) and targetUpsidePct 69.6%; discount for null bullish_prob, no 1wk data, and fwdPe 54.74 — feels more like BUY_PULLBACK than BUY_NOW.
RAREbullish_prob 0.6, weekly fc_long +40.16%, pos_in_21bar_range at 3.81% on 4h (deeply oversold, not chasing), plus back-to-back analyst PT raises from Morgan Stanley ($74) and Canaccord ($83) with targetUpsidePct 114% — biotech risk keeps it at #3.
Full ranking (11)
#SymbolVerdictScoreRead
1KVYOBUY NOW8.5Only name with bullish_prob=1, fundamental_score 7.25, and 4h/1d forecasts of +18.97%/+12.73% short into +32.81%/+27.81% long — screen thesis fully confirmed.
2KRMNBUY PULLBACK7.4Enormous forecast magnitudes (4h fc_mid +58.91%, 1d +38.89%) and 69.6% analyst upside, but null bullish_prob, missing 1wk, and fwdPe 54.74 warrant a better entry.
3RAREBUY PULLBACK6.2Deeply oversold (4h pos 3.81%), weekly fc_long +40.16%, dual analyst PT raises, but biotech binary risk and -73.77% operMargin cap the size.
4BTDRWAIT5.4bullish_prob 1 and CSO bought 25k shares, but 4h dd -28.92% and weekly fc_long -21.19% show a broken higher-timeframe structure.
5GLXYWAIT5.0Solid daily setup (fc_long +14.94%, pos 90.11%) and 74.8% analyst upside, but Citi just cut PT to $26 and no weekly data to confirm trend.
6RDWWAIT4.4Trump launch-goal narrative is real, but 4h fc_short -28.83% and fc_long -28.13% say the tape disagrees; only 1 timeframe available.
7SEIWAIT4.2Great fundamental_score 5.5 and peg 0.33, but 4h recent -31.6% with dd -32.5% and only 4h available — no confirmation to buy here.
8GENIWAIT3.81wk +103.83% recent gain but forecasts fade -0.56% long; pos at 91.26% weekly = chasing, and bullish_prob is 0.
9DLOAVOID3.0Fundamental_score 8 is misleading — every timeframe forecasts negative (1wk fc_long -15.3%) and all positions at 90%+ = distribution top.
10GRNDAVOID2.6Despite fundamental_score 8, forecasts are -27.43%/-25.76%/-11.36% on 4h and all timeframes decline — deteriorating trend, expected_return -4.1%.
11DAVEAVOID2.0Fundamental_score 8 but 1wk fc_long -65.57% and 4h fc_long -53.68% — the tape is screaming that the 91% weekly move is topping.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.